A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease.

PubWeight™: 0.92‹?›

🔗 View Article (PMID 11342685)

Published in Neurology on May 08, 2001

Authors

M T Hu1, S J White, A H Herlihy, K R Chaudhuri, J V Hajnal, D J Brooks

Author Affiliations

1: MRC Cyclotron Building, Medical Research Council Clinical Sciences Centre, and Division of Neuroscience (Drs. Hu and Brooks), and Robert Steiner MR Unit (Drs. Hu, White, Herlihy, and Hajnal), Imperial College School of Medicine, Hammersmith Hospital.

Articles by these authors

Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med (2000) 6.21

Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer (1978) 5.25

Multi-atlas based segmentation of brain images: atlas selection and its effect on accuracy. Neuroimage (2009) 5.16

Area V5 of the human brain: evidence from a combined study using positron emission tomography and magnetic resonance imaging. Cereb Cortex (1993) 4.79

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology (2006) 4.06

On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics (1976) 3.82

Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain (1995) 3.71

In-vivo measurement of activated microglia in dementia. Lancet (2001) 3.51

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49

Evidence for striatal dopamine release during a video game. Nature (1998) 3.28

Use of multicoil arrays for separation of signal from multiple slices simultaneously excited. J Magn Reson Imaging (2001) 3.21

Normal and abnormal white matter tracts shown by MR imaging using directional diffusion weighted sequences. J Comput Assist Tomogr (1990) 3.06

Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci (1999) 3.06

The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86

The functional anatomy of motor recovery after stroke in humans: a study with positron emission tomography. Ann Neurol (1991) 2.84

Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76

Motor sequence learning: a study with positron emission tomography. J Neurosci (1994) 2.71

Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab (1996) 2.66

Statistical errors in papers in the British Journal of Psychiatry. Br J Psychiatry (1979) 2.38

Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis (2004) 2.29

Anatomy of motor learning. I. Frontal cortex and attention to action. J Neurophysiol (1997) 2.29

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry (1998) 2.24

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet (2005) 2.18

Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet (1994) 2.17

Microstructured magnetic materials for RF flux guides in magnetic resonance imaging. Science (2001) 2.16

Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study. Brain (1997) 2.15

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry (2008) 2.12

Inadvertent esophageal intubation in the field: reliance on a fool's "gold standard". Acad Emerg Med (1997) 2.07

Anatomy of motor learning. II. Subcortical structures and learning by trial and error. J Neurophysiol (1997) 1.97

Nine unknown rearrangements in 16p13.3 and 11p15.4 causing alpha- and beta-thalassaemia characterised by high resolution multiplex ligation-dependent probe amplification. J Med Genet (2005) 1.96

Contrasting cortical and subcortical activations produced by attentional-set shifting and reversal learning in humans. J Cogn Neurosci (2000) 1.94

Relation between cerebral activity and force in the motor areas of the human brain. J Neurophysiol (1995) 1.91

Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology (2006) 1.88

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain (1996) 1.87

Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol (1992) 1.86

The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol (1999) 1.85

Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry (2005) 1.83

Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80

Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology (2005) 1.77

Magnetic resonance imaging of total body fat. J Appl Physiol (1985) (1998) 1.76

Self-initiated versus externally triggered movements. II. The effect of movement predictability on regional cerebral blood flow. Brain (2000) 1.75

Combination of signals from array coils using image-based estimation of coil sensitivity profiles. Magn Reson Med (2002) 1.73

The effect of ethanol on alcohol-responsive essential tremor: a positron emission tomography study. Ann Neurol (1996) 1.70

Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology (2009) 1.70

Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol (2013) 1.61

Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology (2003) 1.61

Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med (1999) 1.59

Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry (1996) 1.58

A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections. Ann Neurol (1993) 1.58

What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58

A PET study of voluntary movement in schizophrenic patients experiencing passivity phenomena (delusions of alien control). Brain (1997) 1.57

Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry (1999) 1.57

Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain (1999) 1.54

Physiological assessment of aspects of autonomic function in patients with secondary progressive multiple sclerosis. J Neurol (1993) 1.52

Reduction of CSF and blood flow artifacts on FLAIR images of the brain with k-space reordered by inversion time at each slice position (KRISP). AJNR Am J Neuroradiol (2001) 1.52

Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol (2001) 1.52

In vitro antibacterial properties of BRL 36650, a novel 6 alpha-substituted penicillin. Antimicrob Agents Chemother (1984) 1.50

Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2010) 1.50

MR of the brain using fluid-attenuated inversion recovery (FLAIR) pulse sequences. AJNR Am J Neuroradiol (1992) 1.49

Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry (2000) 1.48

Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain (1991) 1.47

Magnetic resonance imaging of spinal cord in multiple sclerosis by fluid-attenuated inversion recovery. Lancet (1993) 1.46

Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology (1999) 1.46

Combined pedunculopontine-subthalamic stimulation in Parkinson disease. Neurology (2012) 1.45

Restless legs syndrome. J Neurol Neurosurg Psychiatry (2001) 1.44

Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol (1992) 1.43

L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles. Mov Disord (1995) 1.43

Subcutaneous apomorphine in Parkinson's disease. BMJ (1998) 1.41

Updated guidelines for the management of Parkinson's disease. Hosp Med (2001) 1.41

Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry (1995) 1.39

Association of abnormal cerebellar activation with motor learning difficulties in dyslexic adults. Lancet (1999) 1.39

The need for evaluation of gastroesophageal reflux in brain-damaged children referred for feeding gastrostomy. J Pediatr Surg (1981) 1.39

The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol (1990) 1.39

The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain (1993) 1.38

Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain (1999) 1.37

[11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology (1999) 1.36

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A (1997) 1.36

Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet (1988) 1.35

What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35

Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (1997) 1.34

International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology (2009) 1.34

Preliminary report: activation of the cerebellum in essential tremor. Lancet (1990) 1.33

Identification of the cerebral loci processing human swallowing with H2(15)O PET activation. J Neurophysiol (1999) 1.33

Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology (1996) 1.32

Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain (1993) 1.31

Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol (2000) 1.30

Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther (2004) 1.30

Mills' and other isolated upper motor neurone syndromes: in vivo study with 11C-(R)-PK11195 PET. J Neurol Neurosurg Psychiatry (2005) 1.29

Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol (1997) 1.29

Assessment of brain growth in early childhood using deformation-based morphometry. Neuroimage (2007) 1.28

Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology (2006) 1.27

Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy. Lancet (1979) 1.27

The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain (2001) 1.26

Motor reorganization in acquired hemidystonia. Ann Neurol (1995) 1.25

Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain (2005) 1.24

Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology (1992) 1.24